Telix Pharmaceuticals Limited (ASX: TLX)
Health Care · Biotechnology · AU
AU$15.85
-0.13% today · +2.9% 1Y
Telix Pharmaceuticals Limited (ASX: TLX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.76B and employs 1,152 people.
Over the last twelve months the share price has gained 2.9%, trading between 8.26 and 18.22.
Tweenvest scores Telix Pharmaceuticals Limited across four factors: quality 59/100, value 60/100, growth 100/100. Its strongest factor is growth.
TLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.76B
- Revenue (TTM)
- $890.78M
- P/E
- 114.95
- EPS
- 0.10
- Dividend yield
- —
- Beta (5Y)
- 0.56
- 52-week high
- AU$18.22
- 52-week low
- AU$8.26
- Avg volume (3M)
- —
- Shares outstanding
- 339.78M
- Employees
- 1,152
- Next earnings
- —
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
- ISIN
- AU000000TLX2
- Founded
- 2015
- Listed since
- Nov 14, 2017
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Dizal (Jiangsu) Pharmaceutical Co., Ltd.SHSE: 688192 | $4.16B | CN¥59.95 | +3.34% |
| Suzhou Zelgen Biopharmaceuticals Co., Ltd.SHSE: 688266 | $4.12B | CN¥104.25 | -5.23% |
| Tango Therapeutics, Inc.NasdaqGM: TNGX | $4.01B | $24.17 | +1.51% |
| Relay Therapeutics, Inc.NasdaqGM: RLAY | $3.92B | $17.92 | +0.22% |
| Beijing Tiantan Biological Products Co., Ltd.SHSE: 600161 | $3.76B | CN¥12.73 | +1.11% |
| Hualan Biological Engineering Inc.SZSE: 002007 | $3.64B | CN¥13.35 | +0.07% |
| Veracyte, Inc.NasdaqGM: VCYT | $3.64B | $43.53 | -3.76% |
| Legend Biotech CorporationNasdaqGS: LEGN | $3.61B | $18.29 | -1.77% |
Figures last refreshed Oct 11, 2026.